Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorMandel, Nil Molinas
dc.contributor.authorSelcukbiricik, Fatih
dc.contributor.authorKanitez, Metin
dc.contributor.authorYalcin, Suayip
dc.contributor.authorTural, Deniz
dc.contributor.authorErdamar, Sibel
dc.contributor.authorDemir, Gokhan
dc.date.accessioned2019-08-13T12:10:23Z
dc.date.accessioned2019-08-13T15:57:26Z
dc.date.available2019-08-13T12:10:23Z
dc.date.available2019-08-13T15:57:26Z
dc.date.issued2016
dc.identifier.issn1107-0625
dc.identifier.urihttp://hdl.handle.net/11446/2515
dc.descriptionWOS: 000376829900010en_US
dc.descriptionPubMed ID: 27273945en_US
dc.description.abstractPurpose: Gastrointestinal stromal tumors (GISTs) are common tumors of the gastrointestinal tract. Their most frequent location is the stomach. Although the clinical and pathological characteristics of the disease are well-known, the clinical and pathological characteristics and the response to treatment are not clear in elderly patients. The purpose of this study was to evaluate the characteristics of GISTs in elderly patients with an aim at improving the therapeutic methodology and survival. Methods: In this study, clinicopathological characteristics, evaluation of treatments administered and survival analyses were performed in patients aged 65 years or above, whose data were registered via a web-based patient records system following admission to three centers. Results: A total of 85 patients aged 65 years or above were included in the study. According to the risk classification, 24 (28.2%) were in the low risk group, 20 (23.5%) in the moderate risk group, and 41 (48.3%) in high risk group, while no patient was in the very low risk group. At baseline, 70% of the patients had localized disease and 30% metastatic disease. The tumor was located in the stomach in the majority of the patients (45.6%). The tumor size most commonly seen was 5-10 cm (N=31; 36.4%). Of the 85 patients 23 (27%) were treated with imatinib 400 mg/d. Eight patients (9.4%) with metastatic disease switched from imatinib to sunitinib. At a median follow-up of 76 months (range 1-323), median overall survival (OS) was 72 months, without significant difference between elderly and younger patients. Conclusion: Clinicopathological characteristics and their prognostic impact on the disease course of elderly GIST patients should be elucidated in depth. Since age didn't show prognostic importance, other parameters should be used as prognostic/predictive factors in the tyrosine kinase inhibitors era in order to obtain improved therapeutic results.en_US
dc.language.isoengen_US
dc.publisherZERBINIS MEDICAL PUBLen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectgastrointestinal stromal tumoren_US
dc.subjectimatiniben_US
dc.subjectold ageen_US
dc.subjectsurvivalen_US
dc.subjecttreatmenten_US
dc.titleClinical and pathological characteristics and their effect on survival in elderly patients with gastrointestinal stromal tumorsen_US
dc.typearticleen_US
dc.relation.journalJOURNAL OF BUONen_US
dc.departmentDBÜen_US
dc.identifier.issue2en_US
dc.identifier.volume21en_US
dc.identifier.startpage360en_US
dc.identifier.endpage365en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Mandel, Nil Molinas] Univ Koc, Dept Med Oncol, 40 Davutpasa St, TR-34200 Istanbul, Turkey -- [Selcukbiricik, Fatih -- Kanitez, Metin] Amer Hosp, Dept Med Oncol, Istanbul, Turkey -- [Yalcin, Suayip] Hacettepe Univ, Fac Med, Internal Med, Dept Med Oncol, TR-06100 Ankara, Turkey -- [Tural, Deniz] Bakirkoy Sadi Konuk Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Erdamar, Sibel] Bilim Univ, Dept Pathol, Fac Med, Istanbul, Turkey -- [Dogusoy, Gulen] Istanbul Univ, Cerrahpasa Fac Med, Dept Pathol, Istanbul, Turkey -- [Demir, Gokhan] Acibadem Univ, Dept Med Oncol, Fac Med, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster